Cardiorenal outcomes of empagliflozin versus dapagliflozin in primary prevention among patients with type 2 diabetes: A nationwide cohort study - PubMed
6 hours ago
- #SGLT2 inhibitors
- #primary prevention
- #type 2 diabetes
- This nationwide cohort study compared empagliflozin and dapagliflozin for cardiorenal outcomes in type 2 diabetes patients without prior cardiovascular or renal disease.
- The primary outcome, a composite of cardiovascular death, myocardial infarction, stroke, heart failure hospitalization, or end-stage renal disease, showed no significant difference between the two drugs (HR 0.98, 95% CI 0.89-1.09).
- Secondary outcomes, including major adverse cardiovascular events, were also comparable, with consistent results in sensitivity analyses.
- Empagliflozin and dapagliflozin demonstrated similar effectiveness for primary prevention, suggesting clinical interchangeability in real-world practice.